Reudyn launches a consumer exoskeleton brand — the Hip X26 has no price yet
A new wearable-robotics brand entered the exoskeleton market on August 12: China’s Reudyn, positioning itself around “human-centered mobility” rather than the industrial or clinical framing most powered exoskeletons use. Its first product, the Hip X26, is a hip-worn assist device aimed at everyday walking, running and outdoor mobility for able-bodied consumers — closer to an e-bike than a rehab tool.
What Reudyn hasn’t said yet is more notable than what it has. No price. No weight. No battery life or power output. No confirmed sales channel. The company says those details will follow “ahead of availability,” with commercial launch targeted for September 2026. Until then, the Hip X26 is a name and a category, not a product you can order.
That puts it in familiar territory for this segment. Every powered exoskeleton we track — Ekso Bionics’ EVO, Wandercraft’s Atalante X, HeroWear’s Apex 2 — is sold direct to buyers but without a published list price; you get a quote after a sales call, not a number on a page. Reudyn is pitching a genuinely different buyer (a consumer paying out of pocket, not a hospital or logistics operator on a procurement cycle), which is exactly the segment where an opaque, quote-only price would be the most out of place. If Reudyn wants the Hip X26 to read as a consumer product rather than another enterprise-quoted medical device with a marketing wrapper, publishing a real number at launch is the simplest way to prove it.
We’ll add the Hip X26 to the index once Reudyn discloses a price or verifiable specs — right now there’s nothing to put in a spec sheet.
Sources
Primary sources referenced in this article. Prices in the tables come from the live index and carry their own as-of dates.
- HeroWear: Apex 2 — official product page (herowearexo.com)